The present and progress of common drug therapy in treating senile osteoporosis

doi:10.3877/cma.j.issn.2096-0263.2019.06.011

Abstract

Abstract:

Osteoporosis is a very common disease among elderly people but still no effective therapy to cure. Drug therapy as the prevent treatment in osteoporosis has been proved valuable in releasing the clinical symptom and prevent the progress of fracture. With the increasing variety of osteoporosis drugs, the comprehension of the effect and side effect of drugs are growing. The laboratory and clinical studies of osteoporosis were reviewed, and the efficacy and safety of drug were summarized in this article, hopefully it can provide theoretical basis for clinical treatment of osteoporosis.

Key words: Osteoporosis, Drug therapy, Bisophosphonates, Parathyroid hormone

Mo Li, Haiwei Wang, Lijuan Wang, Jianlin Xiao, Zhongli Gao, Hanqing Cai. The present and progress of common drug therapy in treating senile osteoporosis[J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2019, 05(06): 365-369.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlngkykfdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2096-0263.2019.06.011

https://zhlngkykfdzzz.cma-cmc.com.cn/EN/Y2019/V05/I06/365

References 45

1	Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures [J]. J Bone Miner Res, 2005, 20(7): 1185-1194.
2	Ström O, Borgström F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) [J]. Arch Osteoporos, 2011, 6: 59-155.
3	张智海，张智若，刘忠厚,等.中国大陆地区以-2.0SD为诊断标准的骨质疏松症发病率回顾性研究[J].中国骨质疏松杂志, 2016, 22(1): 1-8.
4	Eriksen EF. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease [J]. Endocr Rev, 1986, 7(4): 379-408.
5	Cosman F, De Beur SJ, Leboff MS, et al. Clinician's guide to prevention and treatment of osteoporosis [J]. Osteoporos Int, 2014, 25(10): 2359-2381.
6	Holick MF. Vitamin D deficiency [J]. N Engl J Med, 2007, 357(3): 266-281.
7	Larsen ER, Mosekilde L, Foldspang A. Vitamin D and Calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: A pragmatic population-based 3-year intervention study [J]. J Bone Miner Res, 2004, 19(3): 370-378.
8	Langdahl BL, Harsløf T. Medical treatment of osteoporotic vertebral fractures [J]. Ther Adv Musculoskelet Dis, 2011, 3(1): 17-29.
9	Fleisch H, Russell RG, Bisaz S, et al. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution [J]. Calcif Tissue Res, 1968, 2(1): Suppl:10-Suppl10a.
10	Reitsma PH, Teitelbaum SL, Bijvoet OL, et al. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro [J]. J Clin Invest, 1982, 70(5): 927-933.
11	张禄锴，马剑雄，李风波,等.双膦酸盐类药物治疗骨质疏松症的研究进展[J].中华老年骨科与康复电子杂志, 2017, 3(3): 184-187.
12	Paskins Z, Warburton L. Bisphosphonates beyond five years [J]. BMJ, 2016, 352: i264.
13	Blum L, Cummings K, Goulet JA, et al. Atypical femur fractures in patients receiving bisphosphonate therapy: etiology and management [J]. Eur J Orthop Surg Traumatol, 2016, 26(4): 371-377.
14	Schilcher J, Koeppen V, Aspenberg P, et al. Risk of atypical femoral fracture during and after bisphosphonate use [J]. N Engl J Med, 2014, 371(10): 974-976.
15	Bonomi M, Nortilli R, Molino A, et al. Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis [J]. Med Oncol, 2010, 27(2): 224-229.
16	Lam J. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand speci city [J]. J Clin Invest, 2001, 108(7): 971-979.
17	Rossini M, Adami G, Adami S, et al. Safety issues and adverse reactions with osteoporosis management [J]. Expert Opin Drug Saf, 2016, 15(3): 321-332.
18	Lacey DL, Boyle WJ, Simonet W, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab [J]. Nat Rev Drug Discov, 2012, 11(5): 401-U150.
19	Papapoulos S. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis:results from the FREEDOM Extension study [J]. Osteoporos Int, 2015, 26(12): 2773-2783.
20	Cummings SR, San Martin J, Mcclung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [J]. N Engl J Med, 2009, 361(8): 756-765.
21	Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women:results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation [J]. JAMA, 1999, 281(23): 2189-2197.
22	Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density,serum cholesterol concentrations,and uterine endometrium in postmenopausal women [J]. N Engl J Med, 1997, 337(23): 1641-1647.
23	Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: Multiple outcomes of raloxifene evaluation [J]. Obstet Gynecol, 2004, 104(4): 837-844.
24	Malozowski S. Lasofoxifene for postmenopausal women with osteoporosis [J]. N Engl J Med, 2010, 362(23): 2227.
25	Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis [J]. N Engl J Med, 2001, 344(19): 1434-1441.
26	Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis [J]. N Engl J Med, 2007, 357(20): 2028-2039.
27	Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis a randomized clinical trial [J]. JAMA, 2016, 316(7): 722-733.
28	Meunier PJ, Roux C, Seeman E, et al. The effects of Strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis [J]. N Engl J Med, 2004, 350(5): 459-468.
29	Bonnelye E, Chabadel A, Saltel F, et al. Dual effect of Strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro [J]. Bone, 2008, 42(1): 129-138.
30	Marie PJ. Optimizing bone metabolism in osteoporosis:insight into the pharmacologic profile of Strontium ranelate [J]. Osteoporos Int, 2003, 14(3): 9-12.
31	Pernicova I, Middleton ET, Aye M. Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert [J]. Osteoporos Int, 2008, 19(12): 1811-1812.
32	Breart G, Cooper C, Meyer O, et al. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database [J]. Osteoporos In, 2010, 21(7): 1181-1187.
33	Jiang Y, Zhang ZL, Zhang ZL, et al. Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial [J]. Clin Interv Aging, 2014, 9: 121-127.
34	韩阳，李傲航，叶卫丰. 2型糖尿病并发骨质疏松与NLR、RDW和MPV的关系[J].临床和实验医学杂志, 2017, 16(17): 1734-1736.
35	Mahdiniae DA, Menaquinone-7 OA. (vitamin K2): a new perspective [J]. World J Microbiol Biotechnol, 2017, 33(1): 2.
36	Kodama Y, Okamoto Y, Kubota T, et al. Effectiveness of vitamin K2 on osteoporosis in adults with cerebral palsy [J]. Brain Dev, 2017, 39(10): 846-850.
37	Xu T, Wang L, Tao Y, et al. The function of naringin in inducing secretion of osteoprotegerin and inhibiting formation of osteoclasts [J]. Evid Based Complement Alternat Med, 2016: 8981650.
38	Zhu HM, Qin L, Garnero P, et al. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis [J]. Bone, 2010, 47(3): S457-S458.
39	Liu M, Zhong C, He RX, et al. Icariin associated with exercise therapy is an effective treatment for postmenopausal osteoporosis [J]. Chin Med J(Engl), 2012, 125(10): 1784-1789.
40	Ouyang L, Zhang QF, Ruan XZ, et al. Treatment effect of Bushen Huayu extract on postmenopausal osteoporosis in vivo [J]. Exp Ther Med, 2014, 7(6): 1687-1690.
41	Shuai B, Shen L, Zhu R, et al. Effect of Qing'e formula on the in vitro differentiation of bone marrow-derived mesenchymal stem cells from proximal femurs of postmenopausal osteoporotic mice [J]. BMC Complement Altern Med, 2015, 15: 250.
42	Nelson ER, Wardell SE, Mcdonnell DP. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis [J]. Bone, 2013, 53(1): 42-50.
43	Xu XH, Dong SS, Guo Y, et al. Molecular Genetic Studies of Gene Identification for Osteoporosis: The 2009 Update [J]. Endocr Rev, 2010, 31(4): 447-505.
44	Liu YZ, Liu YJ, Recker RR, et al. Molecular studies of identification of genes for osteoporosis: The 2002 update [J]. J Endocrinol, 2003, 177(2): 147-196.
45	Liu YJ, Shen H, Xiao P, et al. Molecular Genetic Studies of Gene Identification for Osteoporosis: a 2004 Update [J]. J Bone Miner Res, 2006, 21(10):1511-1535.

[1]	The Joint Surgery Branch of the Chinese Orthopedic Association, Guangdong’s Medical Association of Osteoporosis And Bone Mineral Research, Foshan Shunde 3rd Peoele’s Hospital. Clinical intervention guideline for using of anti-osteoporosis drugs in postoperative fragile hip fractures in China (2023 Edition) [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 751-764.
[2]	Luqiao Pu, Yongqing Xu, Baochuang Qi, Hongxin Shi, Wei Lin, Pengfei Bu, Yan Bai, Zhifang Tang, Chuan Li. Prospectus on clinical intervention guideline for anti-osteoporosis drugs in postoperative fragile hip fractures in China (2023 edition) [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(05): 747-750.
[3]	Yan Wang, Jianxiong Ma, Shuang Lang, Benchao Dong, Aixian Tian, Yan Li, Lei Sun, Hongzhen Jin, Bin Lu, Ying Wang, Haohao Bai, Xinlong Ma. Research progress in application of exosomes in diagnosis and treatment of osteoporosis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(05): 673-678.
[4]	Changjiao Sun, Peng Yu, Xu Cai, Yongwei Pan. Progress of shoulder arthroplasty in patients with osteoporosis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(02): 253-260.
[5]	Joint Surgery Group of Chinese Orthopaedic Association., Shanghai Changzheng Hospital, Shanghai 200003, China. Management standard of chronic bone disease for community hospitals [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(01): 1-10.
[6]	Zeying Jiang, Anting Wang, Jiaoli Wang, Ci Chen, Qiuling Zhou, Yanjuan Huang, Fang Zhou, Yan Xue, Jianfeng Zhou, Wenyong Tan, Meifang Du. Effect of multiple plant oils combination in preventing the chemoradiotherapy induced toxicities [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(06): 523-527.
[7]	Yixian Lu, Zhentao Zhang, Demeng Xia, Jialin Wang. Research progress of the regulating role and mechanism of macrophage polarization in osteoporosis [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(06): 538-541.
[8]	Changying Ye, Jing Xie, Guicong Ding. Research advances in interim treatment of deciduous tooth caries [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(05): 365-370.
[9]	Yueqi Chen, Rui Luo, Han Xiang, Yongyan Yu, Ting Yu. The causal association between osteoporosis and periodontitis: A two-sample Mendelian randomization study [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(04): 292-298.
[10]	Chengren Zhang, Xiongfei Yang, Binbin Du, Lili Liu, Jingjing Li, Chengzhang Zhu, Dewang Wu, Yaochun Lv. A meta-analysis of primary tumor resection in asymptomatic colorectal cancer with unresectable metastases [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 305-310.
[11]	Bitao Wang, Zheng Wang, Guobin Wang. Treatment status and progress of Lynch syndrome [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 332-335.
[12]	Juan Wang, Jun Gao, Yilan Zhou, Xiaohong Li, Bingwei Shi, Meizhen Pan. Relationship between serum IL-2, IL-17 and bone mineral density and their predictive value for osteoporosis [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2023, 09(05): 295-300.
[13]	Xi Zhang, YeQing Liu, Xueying Kang, Bingbing Sun, Yan Liu, Liye Hu, Yaru Zhou. Correlation between serum ferritin and postmenopausal osteoporosis [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2023, 09(03): 166-171.
[14]	Yicheng Guo, Zhipeng Xie, Wanli Liu, Yang Zhao, Yansheng Che, Min Zhao. Characteristic analysis of precordial referred pain caused by osteoporotic vertebral compression fracture in the 12th thoracic vertebrae misdiagnosed as coronary heart disease [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(02): 136-139.
[15]	Xiaohui Bai, Long Zhang, Yongfeng Wang, Yi Feng, Bin Zhao, Zhi Lyu, Chaojian Xu. Comparison of therapeutic effects between unilateral and bilateral percutaneous vertebroplasty for Kummell's disease [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2023, 10(02): 14-18.

Please choose a citation manager

Content to export